Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
OVERVIEW AND OUTLOOK
- Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with Biogen Inc.
- Life Science grows organically by 15.6%, mainly thanks to the Process Solutions business
- Mavenclad and Bavencio drive organic growth of Healthcare; recovery in the Fertility franchise
- Semiconductor Solutions business of Performance Materials grows organically by 8.0%
Outlook for fiscal 2020
- Company expects organic sales growth of 4% to 5% over the previous year and Group net sales of between € 17.1 billion and € 17.5 billion
- Organic growth of EBITDA pre over the previous year excluding provision release between 6% and 8% expected, EBITDA pre in a range between € 5.05 billion and € 5.25 billion
The superb results of the third quarter once again underscore the strength of our diversified business model.
ADDITIONAL INFORMATION
Downloads for the Media
Additional Downloads
- Presentation for Analysts (PDF)
- Financial Statement (XLS)
- Financial Statement (PDF)
- Regional Sector Sales (XLS)
- Summary (PDF)
Annual Reports Archive
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Quarterly Statement
Q3 2020
Merck KGaA, Darmstadt, Germany grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, Reports Strong Third Quarter
Merck KGaA, Darmstadt, Germany, grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
2020/11/12
-
Andreas Cezanne
Financial Communications
-
Constantin Fest
Head of Investor Relations
+49 6151 72-5271+49 6151 72 91-5271